Found 14 matching trials
Study of the Combination of CM082 With Everolimus in Patients With mRCC
PHASE1This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerabilit...
Location
Beijing Cancer Hospital
X-82 to Treat Age-related Macular Degeneration
PHASE2The purpose of this study is to evaluate the safety and efficacy of X-82 in...
Location
Multiple Locations
Pilot Study of X-82 in Patients With Wet AMD
PHASE1The objective of this study is to evaluate the safety and preliminary biolo...
Location
Retina Vitreous Associates Medical Group
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
PHASE1This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinet...
Location
Peking Union Medical College Hospital
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
PHASE1This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinet...
Location
Shanghai East Hospital
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
PHASE1This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerabilit...
Location
Beijing University First Hospital
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
PHASE2The purpose of the study is to determine whether adding vorolanib to atezol...
Location
Washington University School of Medicine
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
PHASE1This partially randomized phase I trial studies the side effects and how we...
Location
University of Wisconsin-Carbone Cancer Center
Phase 1 Study of CM082 in Patients With wAMD
PHASE1This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerabilit...
Location
Peking University People's Hospital
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
PHASE1This study is to evaluate the combination of an investigational drug X-82 w...
Location
Washington University School of Medicine